G.M.'s Ailing China Business Will Deal It a $5 Billion BlowGM is restructuring its Chinese operations due to significant financial losses, forecasting over $5 billion impact on profits.The company anticipates slow recovery in its market performance in China through restructuring efforts.
AstraZeneca's China chief detained in illegal data collection and drug import probe, pharma giant saysAstraZeneca's head of China operations has been detained amid investigations into illegal data collection and drug imports.